Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.42 |
| ▸ | MST1R | Q04912 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | HGF | P14210 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 5/20 | 0.36 |
| ▸ | BRAF | P15056 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369483 | 0.93 | KDR (0.49) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368086 | 0.90 | MET (0.44) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368327 | 0.88 | MET (0.55) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368772 | 0.85 | KDR (0.44) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368364 | 0.83 | KDR (0.52) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL369342 | 0.81 | KDR (0.52) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368467 | 0.81 | KDR (0.55) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368940 | 0.81 | KDR (0.55) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368396 | 0.80 | KDR (0.53) | KDRMETMST1RAURKARPS6KA5 | |
| SCHEMBL368803 | 0.79 | MET (0.53) | KDRMETMST1RAURKARPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | claimed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | claimed |
| EP-2593462-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Zhejiang Beta Pharma Inc. (CN) | 2013-05-22 | — | — | EP | claimed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | claimed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | claimed |
| EP-2593462-B1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS C-MET TYROSINE KINASE INHIBITORS | BETTA PHARMACEUTICALS CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| EP-2593462-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | Zhejiang Beta Pharma Inc. (CN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012006960-A1 | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | ZHEJIANG BETA PHARMA INC. (CN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | MET, RET, ABL1 | KDR 48/4885MET 1/4885MST1R 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.